Video

Q&A with Russell Cohen: Healthcare Economics and Its Impact on IBD

Author(s):

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.

"In the US the insurers don't just pay for the cost of medicine, but they pay for the overall cost of care, and some insurers are actually employers, too. If you can show that a medication per dose, but ends up decreasing hospitalizations, surgeries, ER visits, you actually may save money, or at least be cost neutral," commented Cohen.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.